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Abstract
Introduction: Stroke is the second leading cause of death in the world with 5.9 million deaths in
2010. The high prevalence of skoke in kan and its worrisome complications, as well as treatment
with TPA in Kerman for the first time, and in kan, only a study on the therapeutic effects and side
effects of this treatnent has been proposed. It was decided that the effectiveness and the
complications of this type of treatment in patients with ischemic stroke in Kerman are to be
considered.
Materials and methods: This cross-sectional study was performed on patients with acute cerebral
ischemic stroke on 52 patients who referred to Shafa Hospital of Kerman University of Medical
Sciences from 1394 to 1396. Thrombolytic patients (TPAs) received medication by specialist in
the Kelman Healing Hospital, based on the standard protocol. Finally, NIHSS score, which is a
clinical evaluation criterion for patients, was calculated at the start of treatment and 24 hours later.
Data wer.e analyqedusing SPSS-22 software.
Results: The mean age of participants was 64.1 + 11.6 years. 52Yowere male and 48olo were male.
56Yo had hip replacement, 28Yo had diabetes, 32Yo had ischemic heart disease, 24% had
hyperlipidemia and 24Yo had cigarette smoking. The results of this study showed that 24o/o of
participants had complications of thrombolytic Therap therapy during the hospitalization period-
Of these, one case (2o/o) of deaths was reported. Mean scores of MRS (P : 0.044) and NIHSS @:
0.03376) decreased significantly before admission compared with after admission.
Conclusion: The results showed that thrombolytic therapy forpatients with stroke is relatively safe
and safe, with relatively low side effects and mortality and can be effective in the treatment of
patients with cerebrovascular accident.
Key words: Thrombolytic Therapy, Acute Ischemic Stroke, Kerman
42
*5-1,; ,;,-1:ri l,,.tL.lJ *-il*g orll9
6t"y',rjt ,;s 9 *:il-r;., ,;*.p 9 .,-ti,1 p91e oui.iJlc
.r*t! ei;f.t - *f-;X c'-rii.ils
Sl;,Ul il eGr.*V "A
-t ,- ',-' 'r' l.-,4 !,-'
.:L-l J-.p 
.r.:-rJ-F 6r.: *.iLa- ;L; ,s'o *U ..:lrtf +J5.,r I ;:,53 a-"b ;i,-L .5b an*i
3 
-.#
:i*; o, , 
-!-J3 gt-:.: -l,-- * da; . -- -
g1.6**s .lrl*bli ;;5o,rl1.a.ai *,oU,',r-l;_
45," q y:^* 
..r1t1,":t -rr rt,lt, *!--J9a"S i .f J* S ,,-li=,;l \-*)-f:;19;-c ;-o;
.5F* JL= ,-s.-"s*
€-9^^c ,-.-fu-*, .gl,iSJ at;J *tLrJ *---
,gr9l.:;**s 7|:,a gL;rcl9 Li-6lr +JLl ;s*-\ lYqY1Pl1q * - _-




r"S^ gl ar^> ,Sl tSt
ffi
.;p L*i 9y** la +^U irL-U diiJ _r* : ..r,;
